Depo-Provera Side Effects Long Term: The Complete Guide (Beyond Meningioma)

Last updated: April 2026

By Depo-Provera Claims Resource Center Published: March 20, 2026 11 min read

Most people searching for "Depo-Provera side effects long term" want to understand what years of this drug actually do to the body — not just what's on the standard drug information sheet. The honest answer: it's complicated. Long-term Depo-Provera use is associated with a range of effects, some reversible and some not. The most serious — meningioma — earned an FDA black box warning in 2024. But it's far from the only concern.

How Depo-Provera Works in Your Body

Depo-Provera contains medroxyprogesterone acetate (MPA), a synthetic progestin, at 150mg per injection. It works by suppressing ovulation, thickening cervical mucus, and thinning the uterine lining. Because it's injected rather than swallowed, MPA bypasses the digestive system and enters the bloodstream directly — resulting in much higher hormone concentrations than oral progestin contraceptives.

Those elevated MPA levels, sustained over 12–13 weeks per injection and then repeated over years, are what produce both the contraceptive effect and the long-term health effects described below. MPA is not the same as the progesterone your body naturally produces. It's more potent, more stable, and more persistent.

Meningioma: The Most Serious Depo-Provera Long-Term Side Effect

In August 2024, the FDA added a black box warning — its highest-level safety alert — to Depo-Provera, linking long-term use to an increased risk of meningioma, a type of brain tumor. A 2023 study in the British Medical Journal found that women who used injectable MPA had a 5.6 times higher risk of developing a meningioma requiring surgery compared to non-users.

Meningiomas grow on the protective membranes surrounding the brain. They can cause headaches, vision changes, hearing loss, cognitive changes, seizures, and — if they grow large enough — life-threatening neurological damage. Treatment often involves brain surgery, radiation, or both. Recovery can take months to years, and tumors can recur.

This is the side effect that forms the basis of MDL 3140, the federal litigation against Pfizer (the manufacturer). If you used Depo-Provera for two or more years and have a meningioma diagnosis, this may be legally actionable. See: Depo-Provera Meningioma Symptoms for a full symptom guide.

Bone Density Loss: The Black Box Warning That Came First

Before the 2024 meningioma warning, Depo-Provera already carried a black box warning — for a different reason: bone density loss.

Depo-Provera suppresses estrogen production. Because estrogen is essential for maintaining bone density, long-term use leads to significant bone mineral density (BMD) loss — typically 5–8% or more over 2 years of use. The FDA added that warning in 2004, advising that Depo-Provera should not be used for more than 2 years unless other methods are inadequate.

Here's the part worth sitting with: the FDA issued a two-year use limitation for bone density reasons in 2004. Yet many women were prescribed Depo-Provera for 5, 10, or even 15+ years without anyone ever communicating that limitation. Prolonged bone density loss increases fracture risk and can contribute to osteoporosis — particularly in younger women who haven't yet reached peak bone mass.

Research on whether bone density fully recovers after stopping Depo-Provera is mixed. Most studies show partial recovery in the years after discontinuation, but some research suggests women who used Depo-Provera during adolescence — when bone density is still building — may have lasting effects.

Delayed Return of Fertility

Depo-Provera does not cause permanent infertility, but it causes a significant and often underappreciated delay in the return of ovulation after stopping. Unlike oral contraceptives where fertility typically returns within weeks, after the last Depo-Provera injection:

• 50% of women who want to conceive become pregnant within 10 months of stopping
• 90% of women return to fertility within 18–24 months
• Some women experience fertility delays of up to 2 years or longer

This delay is often not adequately disclosed to patients at the time of prescribing. Women who were prescribed Depo-Provera in their 20s and 30s and experienced prolonged fertility delays after stopping may have faced significantly altered family planning outcomes as a result.

Hormonal Disruption and Menstrual Changes

Depo-Provera dramatically alters the hormonal environment of the body. Long-term effects on menstrual cycles include:

Amenorrhea (absence of periods): By 12 months of use, approximately 50% of Depo-Provera users stop having periods entirely. By 24 months, that figure rises to about 70%. Amenorrhea is often described as a "benefit" in promotional materials, but it can mask underlying conditions (pregnancy, gynecological issues) and carries health implications.

Irregular bleeding: Especially in the first 6–12 months, many users experience unpredictable irregular bleeding or spotting that's difficult to manage.

Post-cessation hormonal rebalancing: After stopping, the body takes time to re-establish natural hormonal cycles. This adjustment period can cause irregular cycles, mood changes, and symptoms similar to hormonal imbalance for months to years.

Estrogen suppression: MPA's estrogen-suppressing effect doesn't just affect bones and fertility. Estrogen plays roles in cardiovascular health, cognitive function, skin health, and sexual function. Long-term suppression can affect all of these systems.

Mental Health Effects

The relationship between Depo-Provera and mental health has been a subject of ongoing research and patient-reported concern for decades. Studies show:

• Women using Depo-Provera report higher rates of depression and mood changes compared to non-hormonal contraceptive users in several observational studies
• A large 2023 Danish cohort study found elevated antidepressant prescription rates in women using progestin-only contraceptives including injectable MPA
• Anxiety, irritability, and emotional lability are commonly reported side effects
• Some women report significant improvements in mood and mental health after stopping Depo-Provera

The FDA's current label lists "mental/mood changes" as a side effect, though it does not specifically list depression as a labeled risk for Depo-Provera. The research base on this topic continues to evolve.

Weight Changes

Weight gain is one of the most commonly reported and documented long-term Depo-Provera side effects. Clinical studies show an average weight gain of 5–10 pounds over 2 years of use, though individual variation is large. Some women gain significantly more weight, particularly with longer use.

The mechanism appears to involve increased appetite driven by hormonal changes, possible metabolic effects of estrogen suppression, and direct effects of MPA on fat distribution. Unlike some other hormonal contraceptives, the weight gain associated with Depo-Provera does not consistently reverse after stopping — the hormonal environment normalizes, but weight loss still requires deliberate effort.

Weight gain itself carries health implications: increased risk of type 2 diabetes, cardiovascular disease, joint problems, and psychological impact. For women who used Depo-Provera for many years and gained significant weight, these downstream health effects may be traceable to the drug.

Cardiovascular and Metabolic Effects

Long-term estrogen suppression from Depo-Provera use may have cardiovascular consequences. Research findings include:

• Adverse effects on lipid profiles — specifically, reduced HDL ("good" cholesterol) in some studies
• Possible effects on insulin sensitivity and glucose metabolism, with implications for diabetes risk
• The WHO classifies Depo-Provera as a Category 2 or 3 contraceptive for women with certain cardiovascular risk factors — meaning its use may be inadvisable for women with hypertension, diabetes, or a history of cardiovascular disease

This is an area where the research is less definitive than for meningioma or bone density — cardiovascular effects appear to be more variable and dependent on individual risk profiles.

Other Long-Term Effects

Headaches: Headaches are among the most commonly reported Depo-Provera side effects and can persist throughout use. (Note: persistent headaches may also be an early symptom of meningioma — see a doctor if headaches are new or changing.)

Hair changes: Some women report hair thinning or hair loss during Depo-Provera use, related to androgen activity of MPA.

Sexual dysfunction: Decreased libido and vaginal dryness (related to estrogen suppression) are documented side effects, particularly with long-term use.

Injection site reactions: Repeated injections can cause local skin reactions. Improper injection technique has been associated with skin dimpling or atrophy at injection sites.

Delayed meningioma development: As discussed above, meningiomas may continue to grow for years after stopping Depo-Provera. Women who stopped the drug years ago should still be aware of meningioma symptoms.

Legal Implications of Long-Term Depo-Provera Side Effects

The Depo-Provera litigation in MDL 3140 focuses specifically on meningioma — that's where the strongest scientific evidence and FDA action exist. But the history of Depo-Provera's side effect profile, including the 2004 bone density black box warning and decades of patient-reported mental health concerns, provides important context for how the company handled safety disclosures over time.

If you used Depo-Provera for two or more years and have been diagnosed with meningioma, your other long-term health effects — bone density issues, fertility delays, mental health impacts — may also be documented as part of your claim's overall damages picture. Consult an attorney to understand how the full scope of your health history relates to your potential claim.

For more information, see: Do I Qualify for a Depo-Provera Lawsuit? and Depo-Provera Lawsuit 2026 Update.